Abstract:Objective: To investigate the effect of reversing multi-drug resistance and killing tumor cells of mesoporous silica nanoparticles (MSNP) co-delivery system, and to confirm whether combined application of Doxovubicin (DOX) and MDR1 shRNA can exert a synergistic antitumor effect. Methods:Firstly, mesoporous silica nanoparticles were prepared by sol-gel method under room temperature and coated by cationic polymerpolyethylenimine (PEI) on the surface to stay positive charge, which could facilitate its combination with negatively charged MDR1 shRNA in the next step. With the absorption of DOX, an antitumor drug, the drug and gene co-delivery system was then formed. In vitro, drug loading was <br> evaluated by UV-Vis spectrophotometer;antitumor drugs were co-cultured respectively with oral squamous cells carcinoma cells lines KB and resistant cell lines KBV. Then MTT assay was conducted to measure the half maximal inhibitory concentration (IC50); Fluorescence microscope and flow cytometry instrument were used to measure the transfection efficiency of the co-delivery system; Real-Time PCR technique was applied to detect the expression of MDR1 gene;AnnexinV-FITC/7-AAD double staining by flow cytometry was conducted to detect cell apoptosis. Results: The MSNP appeared to have a high dispersibility and homogeneous size by particle size analyzer and transmission electron microscopy (TEM). The formed nanoparticles have a diameter distribution of 100-200 nm, and the surface mesoporous diameter is 3-5 nm. IC50 (KB-DOX) was 182.9 ng/mL, and IC50 (KBV-DOX) was 9 233.5 ng/mL by ultraviolet spectrophotometer. The resistance index of KBV was 50.483 871. The transfection efficiency is 6.73% measured by fluorescence microscope and flow cytometry . The Real-Time PCR test indicated that MDR1 mRNA expression in the co-delivery system decreased dramatically, compared with co-delivery nanoparticles. The results of AnnexinV-FITC/7-AAD double staining showed that the cell apoptosis rates were 12.74% and 10.08% for drug-loaded and gene-loaded nanoparticles respectively, while cell apoptosis rate increased to 25.68%for co-delivery nanoparticles. Conclusion:The results demonstrate that comparing with the pure medicine or genome, the mesoporous silica nanoparticles co-delivery system can effectively reverse multi-drug resistance of tumor and inhibited the growth of tumor dramatically. At the same time, DOX and the MDR1 shRNA can exert synergistic antitumor effect when applied in combination.

Antitumor effects of MsurvivinT34A–CaPi complex-embedded PLGA nanoparticles in combination with Doxil in mice

The use of cationic MPEG-PCL-g-PEI micelles for co-delivery of Msurvivin T34A gene and doxorubicin

Co-Delivery of Doxorubicin and Plasmid by A Novel Fgfr-Mediated Cationic Liposome

Regulation of Ca2+ Signaling for Drug-Resistant Breast Cancer Therapy with Mesoporous Silica Nanocapsule Encapsulated Doxorubicin/siRNA Cocktail

Antitumor Effects of PLGA Nanoparticles Encapsulating the Human PNAS-4 Gene Combined with Cisplatin in Ovarian Cancer.

Polymer-lipid Hybrid Nanoparticles Synchronize Pharmacokinetics of Co-Encapsulated Doxorubicin-Mitomycin C and Enable Their Spatiotemporal Co-Delivery and Local Bioavailability in Breast Tumor.

Enhanced Antitumor Efficacy of Arginine Modified Amphiphilic Nanoparticles Co-Delivering Doxorubicin and Isur-Pdna Via the Multiple Synergistic Effect.

PEG Modified Trimethyl Chitosan Based Nanoparticles for the Codelivery of Doxorubicin and Isur-Pdna

Co-Delivery of Doxorubicin and Survivin Shrna-Expressing Plasmid Via Microenvironment-Responsive Dendritic Mesoporous Silica Nanoparticles for Synergistic Cancer Therapy.

Efficient inhibition of murine breast cancer growth and metastasis by gene transferred mouse survivin Thr34→Ala mutant

Enhanced Lysosomal Escape of pH-Responsive PEI-Betaine Functionalized Carbon Nanotube for the Co-delivery of Survivin siRNA and Doxorubicin.

Local and systemic delivery of mRNA encoding survivin-T34A by lipoplex for efficient colon cancer gene therapy.

Co-delivery of Doxorubicin and MDR1 shRNA by Mesoporous Silica Nanoparticles to Overcome Drug Resistance in vitro

Synergistic treatment of osteosarcoma with biomimetic nanoparticles transporting doxorubicin and siRNA

Folate-Functionalized Magnetic-Mesoporous Silica Nanoparticles for Drug/Gene Codelivery to Potentiate the Antitumor Efficacy.

Bioinspired ginsenoside Rg3 PLGA nanoparticles coated with tumor-derived microvesicles to improve chemotherapy efficacy and alleviating toxicity

Doxorubicin and CpG Loaded Liposomal Spherical Nucleic Acid for Enhanced Cancer Treatment.

Facile Construction of Chloroquine Containing PLGA-Based Pdna Delivery System for Efficient Tumor and Pancreatitis Targeting in Vitro and in Vivo.

A Cationic Prodrug/therapeutic Gene Nanocomplex for the Synergistic Treatment of Tumors.

Co-delivery of Doxorubicin and CRISPR/Cas9 or RNAi-expressing Plasmid by Chitosan-Based Nanoparticle for Cancer Therapy.

Integrated Combination Treatment Using a "smart" Chemotherapy and MicroRNA Delivery System Improves Outcomes in an Orthotopic Colorectal Cancer Model